Date: 2015-06-16
Type of information: R&D agreement
Compound: new ophthalmic therapies targeting retinal diseases
Company: Bayer Healthcare (Germany) Johns Hopkins University (USA - MD)
Therapeutic area: Ophtalmological diseases
Type agreement: R&D
Action mechanism:
Disease: retinal diseases including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt\'s disease, and retinal vein occlusion (RVO)
Details: * On June 16, 2015, Bayer HealthCare and The Johns Hopkins University in Baltimore have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The partners will jointly work on the discovery and development of innovative drugs for the treatment of serious back-of-the-eye diseases that affect many people worldwide, including age-related macular degeneration (AMD), diabetic macular edema (DME), geographic atrophy, Stargardt\'s disease, and retinal vein occlusion (RVO). The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases. Under the agreement, Bayer and the Wilmer Eye Institute of Johns Hopkins will jointly conduct research activities evaluating new targets and disease mechanisms, drug delivery technologies, and biomarkers for back-of-the-eye diseases with high unmet medical need. Both parties will contribute personnel and infrastructure to address important scientific questions. Bayer will have an option for the exclusive use of the collaboration results.
Financial terms: Financial terms of the agreement were not disclosed.
Latest news:
